A wide range of in vitro and in vivo assays for drug testing

• Design and implementation of in vitro assays to validate target specificity

• Design and implementation of in vivo protocol to:

  • a. Collect preclinical toxicity data for new agents, or new combinations of agents in mice (Note: The core will determine maximum tolerated doses for individual and combination therapies, and in turn the relative toxicity of the treatments in question, but will not carry out detailed toxicological studies per se).
  • b. Acquire preclinical efficacy evidences for novel drugs or combinations of drugs allowing for evaluation and documentation of therapeutic potential in mice.

Find a Researcher


For more information, please contact:

John G. Clohessy, PhD
Preclinical Murine Pharmacogenetics Facility Cancer Genetics
Beth Israel Deaconess Cancer Center Department of Medicine
Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center
Harvard Medical School
330 Brookline Avenue, CLS 402
Boston, MA 02115, USA

Tel: (617) 735-2147
Fax: (617) 735-2120